Laboratory of Clinical Science (LCS), National Institute of Mental Health, NIH, Bethesda, MD, USA.
Pharmacogenomics J. 2013 Dec;13(6):551-7. doi: 10.1038/tpj.2012.35. Epub 2012 Sep 11.
A possible side effect of serotonin-enhancing drugs is the serotonin syndrome, which can be lethal. Here we examined possible hypersensitivity to two such drugs, the serotonin precursor 5-hydroxy-L-tryptophan (5-HTP) and the atypical opioid tramadol, in mice lacking the genes for both monoamine oxidase A (MAOA) and MAOB. MAOA/B-knockout (KO) mice displayed baseline serotonin syndrome behaviors, and these behavioral responses were highly exaggerated following 5-HTP or tramadol versus baseline and wild-type (WT) littermates. Compared with MAOA/B-WT mice, baseline tissue serotonin levels were increased ∼2.6-3.9-fold in MAOA/B-KO mice. Following 5-HTP, serotonin levels were further increased ∼4.5-6.2-fold in MAOA/B-KO mice. These exaggerated responses are in line with the exaggerated responses following serotonin-enhancing drugs that we previously observed in mice lacking the serotonin transporter (SERT). These findings provide a second genetic mouse model suggestive of possible human vulnerability to the serotonin syndrome in individuals with lesser-expressing MAO or SERT polymorphisms that confer serotonergic system changes.
血清素增强药物的一种可能的副作用是血清素综合征,它可能是致命的。在这里,我们研究了两种这样的药物——血清素前体 5-羟色氨酸(5-HTP)和非典型阿片类药物曲马多——在缺乏单胺氧化酶 A(MAOA)和 MAOB 基因的小鼠中可能出现的过敏反应。MAOA/B 基因敲除(KO)小鼠表现出基线血清素综合征行为,而与基线和野生型(WT)同窝小鼠相比,5-HTP 或曲马多引起的这些行为反应高度夸大。与 MAOA/B-WT 小鼠相比,MAOA/B-KO 小鼠的组织血清素基线水平增加了约 2.6-3.9 倍。在给予 5-HTP 后,MAOA/B-KO 小鼠的血清素水平进一步增加了约 4.5-6.2 倍。这些夸大的反应与我们之前在缺乏血清素转运蛋白(SERT)的小鼠中观察到的增强血清素药物的反应一致。这些发现提供了第二个遗传小鼠模型,表明 MAO 或 SERT 多态性表达较低的个体可能对血清素综合征具有人类易感性,这些多态性会导致血清素能系统的改变。